Abstract: A process for the preparation of vitamin K2 (MK-7) comprising the culture of Bacillus subtilis mutant strain GN13/72-DSM 17766 deposited on Dec. 5, 2005 at the DSMZ.

Abstract: A process for the preparation of vitamin K2 (MK-7) comprising the culture of Bacillus subtilis mutant strain GN13/72-DSM 17766 deposited on Dec. 5, 2005 at the DSMZ.

Abstract: There is disclosed a fermentation process for producing glutathione which comprises (a) the obtainment of a biomass pre-culture by pre-cultivating, in aerobic conditions, a strain of a glutathione producing yeast wherein the glutathione content per biomass unit is higher than 1.2% w/w; (b) the cultivation, in aerobic conditions, of the resulting biomass pre-culture such that the resulting biomass density is higher than 50 g/l; (c) the activation of the cultured biomass; and (d) the recovery of the cultured biomass, extracting glutathione at a pH equal to or lower than 6 and purifying the resulting glutathione. The process allows to obtain glutathione with high yields and relatively low costs.

Abstract: There is disclosed a fermentation process for producing glutathione which comprises (a) the obtainment of a biomass pre-culture by pre-cultivating, in aerobic conditions, a strain of a glutathione producing yeast wherein the glutathione content per biomass unit is higher than 1.2% w/w; (b) the cultivation, in aerobic conditions, of the resulting biomass pre-culture such that the resulting biomass density is higher than 50 g/l; (c) the activation of the cultured biomass; and (d) the recovery of the cultured biomass, extracting glutathione at a pH equal to or lower than 6 and purifying the resulting glutathione. The process allows to obtain glutathione with high yields and relatively low costs.

Abstract: New antibiotic substances arbitrarily designated M 9026 complex, antibiotic M 9026 factor 1, antibiotic M 9026 factor 2, and antibiotic M 9026 factor 3, produced by fermentation of a strain of the Micromonospora genus. The antibiotics of the invention are antimicrobial and antitumor agents.

Abstract: The present invention relates to a glycopeptide antibiotic arbitrarily designated as A/16686 antibiotic, and to its physiologically-acceptable acid addition salts. Antibiotic A/16686 free base, and its acid addition salts are antibacterial agents, especially active against grampositive microorganisms. The process for producing antibiotic A/16686 by culturing a novel strain of the actinoplanes genus, designated as Actinoplanes sp. ATCC 33076, is a further object of the present invention.

Abstract: The present invention relates to a glycopeptide antibiotic arbitrarily designated as A/16686 antibiotic, and to its physiologically-acceptable acid addition salts. Antibiotic A/16686 free base, and its acid addition salts are antibacterial agents, especially active against grampositive microorganisms. The process for producing antibiotic A/16686 by culturing a novel strain of the Antinoplanes genus, designated as Actinoplanes sp. ATCC 33076, is a further object of the present invention.

Abstract: A biologically pure culture of Actinoplanes sarveparensis.

Abstract: A new antibiotic prepared from aerobic cultivation of Actinoplanes sarveparensis and a method for producing the same from a culture medium.

Abstract: The novel antibiotic, lipiarmycin, is prepared by cultivating Actinoplanes deccanensis A/10655, ATCC 21983, under aerobic conditions in a fermentation broth, from which it is then recovered.

Abstract: Antibiotic activities produced by a variety of Streptosporangium vulgare named Streptosporangium vulgare var. antibioticum var. nov. ATCC 21906. The antibiotic complex contains at least the active fractions named A, B and C.